TL;DR — PQQ is a redox-active cofactor with a genuinely elegant preclinical story: in cell and animal models it phosphorylates CREB and drives PGC-1α, the master switch for building new mitochondria. The human evidence is thin — a handful of small pilots (n≈10–41) on inflammation markers, fatigue, and cognition, no meta-analysis, and several funded by ingredient makers. Trial-anchored dose is 20 mg/day; treat the mitochondrial-biogenesis claim as mechanistically plausible but clinically unproven, and set your expectations to Tier C.
What PQQ does (and why it matters)
Pyrroloquinoline quinone is a small, water-soluble ortho-quinone that acts as a redox cofactor — cycling between oxidized and reduced states it can carry out thousands of catalytic redox reactions before degrading, far more turnovers than typical antioxidants like vitamin C. It is found in trace amounts in foods (fermented soy, parsley, green tea, human milk) and is not classed as a vitamin, though rodent-deprivation work has argued it behaves like a conditionally important nutrient.
The reason it appears on a longevity site is narrower than the marketing suggests: in cultured cells and mice, PQQ activates the CREB → PGC-1α axis that governs mitochondrial biogenesis — the cell's program for manufacturing new mitochondria. Whether that translates into a measurable healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → effect in humans is exactly the open question.
Primary hallmarks targeted: Mitochondrial dysfunction · Chronic inflammation
The strongest single paper is preclinical. Chowanadisai et al. 2010 (PMID 19861415, Journal of Biological Chemistry 285(1):142–152) showed that 10–30 µM PQQ in mouse hepatocytes phosphorylated CREB at Ser133, activated the PGC-1α promoter, and raised mitochondrial DNA content, citrate synthase and cytochrome c oxidase activity, and cellular respiration — and that silencing either CREB or PGC-1α abolished the effect. This is a clean mechanism in cells. The best human data (Harris et al. 2013, PMID 24231099, J Nutr Biochem 24(12):2076–2084) is a crossover in just 10 subjects showing reduced plasma CRP and IL-6 and shifts in urinary mitochondrial-metabolism markers. No RCT has yet confirmed mitochondrial biogenesis in humans.
Mechanism — redox cofactor that talks to PGC-1α
| Proposed mechanism | Evidence source | Hallmark link |
|---|---|---|
| CREB phosphorylation → PGC-1α induction | Mouse hepatocytes (PMID 19861415) | Mitochondrial dysfunction |
| Increased mtDNA, NRF-1/2, Tfam expression | Cell-culture mechanism (PMID 19861415) | Mitochondrial dysfunction |
| Lower CRP / IL-6, altered mito metabolites | Human crossover, n=10 (PMID 24231099) | Chronic inflammation |
| Multi-turnover redox cycling (antioxidant) | In vitro quinone chemistry | Mitochondrial dysfunction |
The mechanism is real and specific — this is not a generic "antioxidant" claim. What is missing is the bridge from a cell dish to a person: the biogenesis pathway has been demonstrated in vitro and in rodents, while the human work has measured downstream inflammation and subjective endpoints rather than actual mitochondrial content.
Read the evidence tension honestly
PQQ has one of the better mechanistic stories among mitochondrial supplements and one of the thinner human ones. The mitochondrial-biogenesis pathway (CREB/PGC-1α) is well-characterized in cells; the human trials are small, short, heterogeneous in endpoint, and several were sponsored by ingredient suppliers (BioPQQ). That does not make them worthless — it means you should weight them as hypothesis-generating pilots, not confirmation.
Evidence summary — small pilots, no meta-analysis
| Study | Design | N | Key reported outcome | Tier |
|---|---|---|---|---|
| Chowanadisai 2010 (PMID 19861415) | In vitro / mouse cells | — | CREB→PGC-1α→↑mtDNA, respiration | C (preclinical) |
| Harris 2013 (PMID 24231099) | Human crossover | 10 | ↓CRP, ↓IL-6; shifted mito metabolites | C (small pilot) |
| Itoh 2016, BioPQQ (PMID 26782228) | RCT, elderly | 41 | ↑ selected attention/visuospatial scores | C (small, sponsored) |
| Tamakoshi 2023 (PMID 36807425) | RCT, adults 20–65 | ~66 | Age-stratified memory/processing gains | C (small) |
| Dihydro-PQQ mixture 2024 (PMID 38908296) | RCT, MCI elderly | 34 | ↑BDNF, ↑brain NAA; MMSE n.s. between groups | C (small, combination product) |
← Swipe for more columns →
Consensus: Tier C. The inflammation signal (CRP/IL-6) is the most reproducible human finding but rests on tiny samples. Cognitive trials are small, short, use different batteries, and the 2024 MCI trial tested a combination product (dihydro-PQQ plus other ingredients) with no significant between-group MMSE difference. There is no meta-analysis and no hard-outcome or lifespan data. Believe the mechanism; stay skeptical of the magnitude.
Where PQQ disappoints
- Every human trial is tiny. The CRP/IL-6 signal is the most reproducible finding but rests on very small samples; the cognitive trials are small, short, and use different tests — nothing pooled or powered. - The best cognition result isn't PQQ alone. The 2024 MCI trial used a multi-ingredient dihydro-PQQ blend and showed no significant MMSE difference — a benefit from a blend isn't evidence for PQQ. - The mitochondrial-biogenesis story is mostly preclinical. Believe the mechanism, doubt the magnitude — there's no hard-outcome or lifespan data.
Should you consider PQQ?
Are you looking for a well-proven, first-line mitochondrial intervention?
Choose better-evidenced options first — CoQ10/ubiquinol has meta-analytic inflammation data, and NAD+ precursors (NMN, NR) have larger human trials
As a low-risk experimental add-on for mitochondrial/inflammation goals, a 12-week 20 mg/day trial with tracked markers is reasonable
Pregnant, nursing, or on anticoagulants — human safety data are limited; get physician clearance first
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol & form selection
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 20 mg/day | The dose used in most human cognition/fatigue trials (BioPQQ disodium salt) |
| Lower reference | ~0.2–0.3 mg/kg/day | Dose range in the Harris 2013 inflammation crossover |
| Form | PQQ disodium salt (e.g. BioPQQ) | The form actually studied in human trials |
| Timing | AM, with food | Commonly taken in the morning; often paired with CoQ10 |
| Duration before reassessing | 12 weeks | Matches the cognition-trial window |
Week-one setup checklist
- [ ] Confirm the label states PQQ disodium salt and a 20 mg dose — this is the studied material and amount.
- [ ] Record a baseline hs-CRP before starting so you can judge the one reproducible human signal.
- [ ] Log energy/fatigue and any subjective cognitive change weekly — these endpoints are subjective, so a structured log matters.
Add PQQ to your stack
PQQ is a native Stack Architect compound. Its mitochondrial-biogenesis mechanism is thematically complementary to CoQ10 (electron transport) and NAD+ precursors — the Architect will flag those pairings.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| hs-CRP | <1.0 mg/L | Baseline, 12 wk | No movement → the strongest human signal isn't showing for you; reconsider |
| Subjective energy/fatigue (1–10) | Upward trend | Weekly | Flat by wk 12 → discontinue; the effect is small at best |
| Cognitive self-report or app battery | Stable/improved | Baseline, 12 wk | No change → expected for many; don't chase with higher doses |
← Swipe for more columns →
hs-CRP
Your baseline
hs-CRP
Modest downward drift (pilot-level evidence only)
Safety, red flags, and contraindications
- Generally well tolerated in the short trials to date — no significant adverse events reported at 20 mg/day over 8–12 weeks.
- Long-term human safety is not established — trials are weeks long, not years.
Thin safety data — don't over-extrapolate
- Pregnancy / nursing — no adequate human safety data; avoid.
- Anticoagulant / antiplatelet therapy — quinones can be redox-active; data on interaction are lacking, so consult a physician.
- High doses — some rodent work shows dose-dependent effects that don't scale linearly; there is no basis for exceeding studied human doses (~20 mg/day). More is not established as better.
- Combination products — several "PQQ" cognition results come from multi-ingredient formulas (e.g. the 2024 dihydro-PQQ mixture); a benefit from a blend is not evidence for PQQ alone.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| CoQ10 (Ubiquinol) | Classic mitochondrial pairing — PQQ proposed to build mitochondria, CoQ10 supports electron transport within them; evaluate as complementary, not proven-additive | CoQ10 module |
| NMN | NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → precursor supplying the cofactor that PGC-1α-driven mitochondrial machinery depends on | NMN module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Anticoagulants / antiplatelets | PQQ is a redox-active quinone; interaction data are lacking | Treat as unknown; consult a physician before combining |
| High doses beyond ~20 mg/day | Rodent work shows non-linear dose effects — more isn't established as better | Stay within studied human doses |
| — | No dedicated human stack-interaction data with other TNiC compounds | Treat pairings as mechanistically reasonable, not clinically demonstrated |
What would change this grade. PQQ is C — a reasonable mitochondrial-biogenesis mechanism with only tiny, mixed human trials. A properly powered trial of PQQ alone on a cognitive or inflammatory endpoint would move it; the blend-based cognition results and small samples keep it capped.
Who should skip PQQ
- Anyone expecting a proven cognitive effect — the strongest cognition result came from a multi-ingredient blend, not PQQ. - Anticoagulant users and pregnancy/nursing — interaction and safety data are lacking. - Anyone tempted to megadose — no basis for exceeding ~20 mg/day.
Personal results template
My PQQ results log
| Date | Week | Dose | hs-CRP | Energy (1–10) | Cognitive note | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | 20 mg | — | — | — | Primary endpoint (trial window) |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: hs-CRP drifts down and subjective energy/fatigue improves consistently — the two endpoints with any human support. - No effect: No marker or subjective change at 12 weeks — the most likely outcome given the thin evidence; discontinue rather than escalate dose. - Stop and reassess: Any new symptom, or any bleeding change if you are on antiplatelet/anticoagulant therapy.
Log your experiment
PQQ is a low-risk, low-certainty n=1 experiment — the honest way to run it is with a baseline marker and a hard 12-week decision point.
Personal journeyReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.